المؤلفون: Brown, Emily, Heerspink, Hiddo J. L., Cuthbertson, Daniel J., Wilding, John P. H.

المصدر: Brown , E , Heerspink , H J L , Cuthbertson , D J & Wilding , J P H 2021 , ' SGLT2 inhibitors and GLP-1 receptor agonists : established and emerging indications ' , LANCET , vol. 398 , no. 10296 , pp. 262-276 . https://doi.org/10.1016/S0140-6736Test(21)00536-5

مصطلحات موضوعية: GLUCOSE-LOWERING DRUGS, ONCE-DAILY LIRAGLUTIDE, OPEN-LABEL, CARDIOVASCULAR OUTCOMES, DOUBLE-BLIND, CVD-REAL, CONTROLLED-TRIAL, EXENATIDE TWICE, ITCA 650, 3.0 MG

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/c61ddd42-3327-4e43-9658-aa129f1ac4b0Test

الإتاحة: https://doi.org/10.1016/S0140-6736Test(21)00536-5
https://hdl.handle.net/11370/c61ddd42-3327-4e43-9658-aa129f1ac4b0Test
https://research.rug.nl/en/publications/c61ddd42-3327-4e43-9658-aa129f1ac4b0Test
https://pure.rug.nl/ws/files/177048219/SGLT2_inhibitors_and_GLP_1_receptor_agonists_established_and_emerging_indications.pdfTest

المصدر: The Lancet. 398(10296):262-276

مصطلحات موضوعية: GLUCOSE-LOWERING DRUGS, DOUBLE-BLIND, ONCE-DAILY LIRAGLUTIDE, CVD-REAL, 3.0 MG, ITCA 650, EXENATIDE TWICE, OPEN-LABEL, CONTROLLED-TRIAL, CARDIOVASCULAR OUTCOMES

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dris___01423::73922021d6b8d162b8232cb0cc404460Test
https://research.rug.nl/en/publications/c61ddd42-3327-4e43-9658-aa129f1ac4b0Test

المؤلفون: Wolffenbuttel, B. H. R., Van Gaal, L., Duran-Garcia, S., Han, J.

المصدر: Wolffenbuttel , B H R , Van Gaal , L , Duran-Garcia , S & Han , J 2016 , ' Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes ' , Diabetes obesity & metabolism , vol. 18 , no. 8 , pp. 829-833 . https://doi.org/10.1111/dom.12669Test

مصطلحات موضوعية: body mass index, exenatide twice daily, type 2 diabetes, PEPTIDE-1 RECEPTOR AGONIST, TO-TARGET TRIAL, BASAL INSULIN, BOLUS INSULIN, SAFETY, LIRAGLUTIDE, MANAGEMENT, DEGLUDEC

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/a839fb7b-db9a-4ba6-addb-f7ad72806a0eTest

الإتاحة: https://doi.org/10.1111/dom.12669Test
https://hdl.handle.net/11370/a839fb7b-db9a-4ba6-addb-f7ad72806a0eTest
https://research.rug.nl/en/publications/a839fb7b-db9a-4ba6-addb-f7ad72806a0eTest
https://pure.rug.nl/ws/files/100802344/Relationship_of_body_mass_index_with_efficacy_of_exenatide_twice.pdfTest

المؤلفون: de Boer, Stefanie Amarens, Lefrandt, Joop Daniel, Petersen, Japke Frida, Boersma, Hendrikus Hessel, Mulder, Douwe Johannes, Hoogenberg, Klaas

المصدر: de Boer , S A , Lefrandt , J D , Petersen , J F , Boersma , H H , Mulder , D J & Hoogenberg , K 2016 , ' The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour ' , International Journal of Clinical Pharmacy , vol. 38 , pp. 144-151 . https://doi.org/10.1007/s11096-015-0219-8Test , https://doi.org/10.1007/s11096-015-0219-8Test

مصطلحات موضوعية: Diabetes mellitus, Eating behaviour, GLP-1 receptor agonist, Insulin therapy, Weight loss, GLUCAGON-LIKE PEPTIDE-1, GLYCEMIC CONTROL, RECEPTOR AGONISTS, EXENATIDE TWICE, PARALLEL-GROUP, WEIGHT-LOSS, LIRAGLUTIDE, THERAPY

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/eebd4f28-0e99-4c7b-802f-b86682bc1f33Test

الإتاحة: https://doi.org/10.1007/s11096-015-0219-8Test
https://hdl.handle.net/11370/eebd4f28-0e99-4c7b-802f-b86682bc1f33Test
https://research.rug.nl/en/publications/eebd4f28-0e99-4c7b-802f-b86682bc1f33Test
https://pure.rug.nl/ws/files/37201761/art_3A10.1007_2Fs11096_015_0219_8.pdfTest

المؤلفون: John P.H. Wilding, Daniel J. Cuthbertson, Hiddo J.L. Heerspink, Emily Brown

المصدر: LANCET

مصطلحات موضوعية: Diabetic ketoacidosis, Type 2 diabetes, Disease, 030204 cardiovascular system & hematology, CONTROLLED-TRIAL, Bioinformatics, CARDIOVASCULAR OUTCOMES, Glucagon-Like Peptide-1 Receptor, GLUCOSE-LOWERING DRUGS, DOUBLE-BLIND, 03 medical and health sciences, 3.0 MG, 0302 clinical medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-like peptide 1 receptor, Heart Failure, CVD-REAL, business.industry, ITCA 650, General Medicine, EXENATIDE TWICE, OPEN-LABEL, medicine.disease, ONCE-DAILY LIRAGLUTIDE, Blood pressure, Diabetes Mellitus, Type 2, Heart failure, business, Kidney disease

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19b6a6b7280fa6a231d91d76905f24a8Test
https://pubmed.ncbi.nlm.nih.gov/34216571Test

المؤلفون: Kothare, Prajakti A, Seger, Mary E, Northrup, Justin, Mace, Kenneth, Mitchell, Malcolm I, Linnebjerg, Helle

مصطلحات موضوعية: exenatide twice daily, pharmacokinetics, oral contraceptive

العلاقة: http://www.biomedcentral.com/1472-6904/12/8Test

الإتاحة: http://www.biomedcentral.com/1472-6904/12/8Test

المؤلفون: Patel, Rajal, Skuba, Katrina, Wild, Michelle, Slack, Marion

مرشدي الرسالة: Slack, Marion, College of Pharmacy, The University of Arizona

مصطلحات موضوعية: diabetes, Weight Loss, exenatide twice daily (ExBID), exentatide once weekly (ExQW)

الإتاحة: http://hdl.handle.net/10150/614272Test
http://arizona.openrepository.com/arizona/handle/10150/614272Test

المؤلفون: Guntram Schernthaner, Baptist Gallwitz, Jonathan E. Shaw, Elise Hardy, Jenny Han

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: medicine.medical_specialty, Percentile, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Drug Resistance, 030209 endocrinology & metabolism, Incretins, Drug Administration Schedule, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Asian People, Internal medicine, Linear regression, Exenatide once weekly, glucagon‐like peptide‐1 receptor agonist, Internal Medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, exenatide twice daily, Glycated haemoglobin, Generalized estimating equation, Glucagon-like peptide 1 receptor, Randomized Controlled Trials as Topic, Glycated Hemoglobin, business.industry, Venoms, Brief Report, Age Factors, Reproducibility of Results, Middle Aged, Postprandial Period, exenatide once weekly, Hypoglycemia, Postprandial, predictors, Diabetes Mellitus, Type 2, Hyperglycemia, Exenatide, Brief Reports, business, Peptides, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da52a51ccd54c2aa5936f4a7424229eTest
http://europepmc.org/articles/PMC5697639Test

المؤلفون: JE Shaw, B Gallwitz, J Han, E Hardy, G Schernthaner

مصطلحات موضوعية: exenatide once weekly, exenatide twice daily, glucagon-like peptide-1 receptor agonist, predictors

العلاقة: http://hdl.handle.net/10536/DRO/DU:30170388Test; https://figshare.com/articles/journal_contribution/Variability_in_and_predictors_of_glycaemic_responses_after_24_weeks_of_treatment_with_exenatide_twice_daily_and_exenatide_once_weekly/20595816Test

الإتاحة: http://hdl.handle.net/10536/DRO/DU:30170388Test
https://figshare.com/articles/journal_contribution/Variability_in_and_predictors_of_glycaemic_responses_after_24_weeks_of_treatment_with_exenatide_twice_daily_and_exenatide_once_weekly/20595816Test

المؤلفون: S. Duran-Garcia, Jenny Han, L. Van Gaal, Bruce H. R. Wolffenbuttel

المساهمون: Lifestyle Medicine (LM), Center for Liver, Digestive and Metabolic Diseases (CLDM), [Wolffenbuttel, B. H. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, HPC AA31, NL-9700 RB Groningen, Netherlands, [Van Gaal, L.] Univ Antwerp Hosp, Dept Endocrinol Diabetol & Metab, Antwerp, Belgium, [Duran-Garcia, S.] Hosp Univ Virgen Valme, Unidad Gest Endocrinol & Nutr, Seville, Spain, [Han, J.] Pharmapace Inc, San Diego, CA USA, alliance of Eli Lilly and Company, Amylin Pharmaceuticals, alliance of Bristol-Myers Squibb, AstraZeneca

المصدر: Diabetes obesity & metabolism, 18(8), 829-833. Wiley
Diabetes, Obesity & Metabolism
Diabetes obesity and metabolism

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, Insulin Glargine, Type 2 diabetes, 030204 cardiovascular system & hematology, 0302 clinical medicine, Endocrinology, Weight loss, Basal insulin, exenatide twice daily, PEPTIDE-1 RECEPTOR AGONIST, Randomized Controlled Trials as Topic, Insulin Lispro, Middle Aged, Management, Treatment Outcome, Bolus insulin, SAFETY, Drug Therapy, Combination, Female, type 2 diabetes, Safety, medicine.symptom, medicine.drug, medicine.medical_specialty, 030209 endocrinology & metabolism, body mass index, Placebo, 03 medical and health sciences, BOLUS INSULIN, DEGLUDEC, Internal medicine, Internal Medicine, medicine, Research Letter, MANAGEMENT, Insulin lispro, Humans, Obesity, Aged, Glycated Hemoglobin, business.industry, Insulin glargine, Liraglutide, Venoms, Body Weight, nutritional and metabolic diseases, medicine.disease, Research Letters, TO-TARGET TRIAL, Diabetes Mellitus, Type 2, LIRAGLUTIDE, Peptide-1 receptor agonist, Exenatide, Human medicine, business, Peptides, Body mass index, BASAL INSULIN, Degludec

وصف الملف: application/pdf; pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::effa393516432ead66e7d8d4dbe479e5Test
https://research.rug.nl/en/publications/a839fb7b-db9a-4ba6-addb-f7ad72806a0eTest